⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RVMD News
Revolution Medicines, Inc. Common Stock
Revolution Medicines’ RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer
globenewswire.com
RVMD
Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot Program
globenewswire.com
RVMD
Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer
globenewswire.com
RVMD